US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NervGen Pharma Corp.

1.76

-0.1500-7.85%

Post-market: 1.800.0400+2.27%19:50 EDT

Volume:1.05M

Turnover:1.88M

Market Cap:190.08M

PE:-3.16

High:1.92

Open:1.92

Low:1.73

Close:1.91

52wk High:6.30

52wk Low:1.58

Shares:108.00M

Float Shares:95.39M

Volume Ratio:2.29

T/O Rate:1.10%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.5570

EPS(LYR):-0.4448

ROE:-757.48%

ROA:-37.70%

PB:15.64

PE(LYR):-3.96

Loading ...

Overview Company News Filings

NervGen Announces It Will Restate Its Audited Annual Financial Statements For The Year Ended December 31, 2025, And Its Unaudited Interim Financial Statements For The Quarter Ended June 30, 2026

Benzinga Earnings

NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments

THOMSON REUTERS

NervGen - Restatement Expected to Reduce Stock-Based Compensation Expense, Warrant Liabilities, and Accumulated Deficit

THOMSON REUTERS

NervGen - Adjustments Have no Impact on Cash, Cash Runway, or Business Operations

THOMSON REUTERS

NervGen - to Restate Fy2025 Audited and Q2 2026 Unaudited Financial Statements

THOMSON REUTERS

Nervgen’s RESTORE Trial Moves Toward Launch: What NVG-291 Could Mean for NGEN Investors

NervGen Pharma Switches Auditor to KPMG US from KPMG Canada

NervGen to Host Inaugural R&D Day Webcast on NVG-291 Program

Nervgen Reports Second Quarter 2026 Financial Results and Provides Business Updates

NervGen Q2 2026 Loss Reflects Continued Spending on NVG-291, NVG-300 Development, Company Says

Press Release: NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

NervGen Pharma price target lowered to $15 from $18 at H.C. Wainwright

Nervgen Pharma Initiated at Outperform by Leerink Partners

Nervgen Pharma Corp : Leerink Partners Initiates Coverage with Outperform Rating; Price Target $10

THOMSON REUTERS

Nervgen Pharma Launches US$ 50 Million At-the-market Equity Offering Via Leerink Partners

H.C. Wainwright Reaffirms Their Buy Rating on NervGen Pharma (NGEN)

H.C. Wainwright Reaffirms Their Buy Rating on NervGen Pharma (NGEN)

NervGen Pharma initiated with a Buy at TD Cowen

NervGen prices 24,000,000-share offering with warrants at US$2.5, targets US$60 million gross proceeds

Nervgen’s CONNECT Trial Termination: What It Means for NGEN Investors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/NGEN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NGEN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGEN\",,,,,undefined,":{"symbol":"NGEN","market":"US","secType":"STK","nameCN":"NervGen Pharma Corp.","latestPrice":1.76,"timestamp":1790884800000,"preClose":1.91,"halted":0,"volume":1051255,"hourTrading":{"tag":"盘后","latestPrice":1.8,"preClose":1.76,"latestTime":"19:50 EDT","volume":92884,"amount":163932.31,"timestamp":1790898631747,"change":0.04,"changeRate":0.022727,"amplitude":0.12358},"delay":0,"changeRate":-0.07853403141361252,"floatShares":95391200,"shares":108000000,"eps":-0.557,"marketStatus":"Not Yet Opened","change":-0.15,"latestTime":"10-01 16:00:00 EDT","open":1.92,"high":1.92,"low":1.7301,"amount":1875599.0261364998,"amplitude":0.099424,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.557,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790928000000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":1.91,"preHourTrading":{"tag":"盘前","latestPrice":1.95,"preClose":1.91,"latestTime":"07:08 EDT","volume":60,"amount":117.400002,"timestamp":1790852901294,"change":0.04,"changeRate":0.020942,"amplitude":0.020942},"postHourTrading":{"tag":"盘后","latestPrice":1.8,"preClose":1.76,"latestTime":"19:50 EDT","volume":92884,"amount":163932.31,"timestamp":1790898631747,"change":0.04,"changeRate":0.022727,"amplitude":0.12358},"volumeRatio":2.290748,"impliedVol":0.0812,"impliedVolPercentile":0.2857},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGEN\",,,,,undefined,":{"symbol":"NGEN","floatShares":95391200,"roa":"-37.70%","roe":"-757.48%","lyrEps":-0.444846,"volumeRatio":2.290748,"shares":108000000,"dividePrice":0,"high":1.92,"amplitude":0.099424,"preClose":1.91,"low":1.7301,"week52Low":1.58,"pbRate":"15.64","week52High":6.3,"institutionHeld":0,"latestPrice":1.76,"eps":-0.557,"divideRate":0,"volume":1051255,"delay":0,"ttmEps":-0.557,"open":1.92,"prevYearClose":5.6,"prevWeekClose":1.94,"prevMonthClose":1.91,"prevQuarterClose":1.91,"fiveDayClose":2.02,"twentyDayClose":2.33,"sixtyDayClose":1.85},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NGEN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"NGEN","fiscalQuarterEnding":"2026/06","expectedEps":-0.09,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"pre","actualEps":-0.37},{"market":"US","date":"2026-05-15","symbol":"NGEN","fiscalQuarterEnding":"2026/03","expectedEps":-0.07,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"post","actualEps":-0.09},{"date":"2026-03-31","symbol":"NGEN","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774944000000,"name":null,"time":"Pre-MKt","dateTimestamp":1774929600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NGEN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NGEN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.875,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.875,"analysts":8,"updateTime":1784001600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NGEN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NGEN","date":"2026-09-30","current":-3.159785,"percent":0.961111,"low":-25.148356,"twenty":-17.005665,"median":-9.17019,"eighty":-5.866178,"high":-4.008234,"avg":-10.794315,"sd":5.756838,"marketCap":206443455},"quantilePoints":[{"date":"2026-01-09","current":-25.148356,"twenty":-24.98651,"median":-24.743741,"eighty":-24.500973,"marketCap":463798962.95},{"date":"2026-01-16","current":-23.484013,"twenty":-24.651705,"median":-24.262661,"eighty":-23.546305,"marketCap":432253265.53},{"date":"2026-01-23","current":-22.238177,"twenty":-24.339127,"median":-23.484013,"eighty":-22.456198,"marketCap":412101315.23},{"date":"2026-01-30","current":-17.441707,"twenty":-24.262661,"median":-22.611928,"eighty":-20.307131,"marketCap":329508465.32},{"date":"2026-02-06","current":-16.382746,"twenty":-23.795472,"median":-22.238177,"eighty":-17.908896,"marketCap":306238051.42},{"date":"2026-02-13","current":-17.441707,"twenty":-23.484013,"median":-19.886661,"eighty":-17.285978,"marketCap":327197651.85},{"date":"2026-02-20","current":-18.220355,"twenty":-23.359429,"median":-18.282647,"eighty":-17.285978,"marketCap":340388899.6},{"date":"2026-02-27","current":-17.753166,"twenty":-22.879782,"median":-18.03348,"eighty":-17.410561,"marketCap":331850071.27},{"date":"2026-03-06","current":-17.223686,"twenty":-22.51849,"median":-17.893323,"eighty":-17.27352,"marketCap":321208516.98},{"date":"2026-03-13","current":-16.382746,"twenty":-22.306698,"median":-17.753166,"eighty":-16.993207,"marketCap":307553178.63},{"date":"2026-03-20","current":-16.957011,"twenty":-22.250635,"median":-17.753166,"eighty":-16.888553,"marketCap":316207550},{"date":"2026-03-27","current":-15.785094,"twenty":-21.714925,"median":-17.597437,"eighty":-16.837477,"marketCap":291516280},{"date":"2026-04-02","current":-18.89617,"twenty":-20.942507,"median":-17.535145,"eighty":-16.702393,"marketCap":347270760},{"date":"2026-04-10","current":-10.676925,"twenty":-19.970755,"median":-17.441707,"eighty":-16.494872,"marketCap":340718966},{"date":"2026-04-17","current":-10.464421,"twenty":-19.238183,"median":-17.254832,"eighty":-16.110604,"marketCap":336672423},{"date":"2026-04-24","current":-9.863583,"twenty":-18.837636,"median":-17.005665,"eighty":-12.953446,"marketCap":318058323},{"date":"2026-05-01","current":-9.064424,"twenty":-18.587877,"median":-16.950192,"eighty":-10.62677,"marketCap":293779061},{"date":"2026-05-08","current":-9.632569,"twenty":-18.344939,"median":-16.86331,"eighty":-10.287304,"marketCap":311583853},{"date":"2026-05-15","current":-9.34654,"twenty":-18.295105,"median":-16.834362,"eighty":-10.043494,"marketCap":300253531},{"date":"2026-05-22","current":-9.812417,"twenty":-18.145605,"median":-16.66306,"eighty":-9.800918,"marketCap":297825605},{"date":"2026-05-29","current":-7.287863,"twenty":-18.008563,"median":-16.66306,"eighty":-9.72533,"marketCap":220902522},{"date":"2026-06-05","current":-7.091826,"twenty":-17.902667,"median":-16.382746,"eighty":-9.634252,"marketCap":213468303},{"date":"2026-06-12","current":-6.717699,"twenty":-17.87775,"median":-16.216296,"eighty":-9.423447,"marketCap":200723927},{"date":"2026-06-18","current":-7.855923,"twenty":-17.87775,"median":-15.872071,"eighty":-9.364073,"marketCap":232584867},{"date":"2026-06-26","current":-6.880017,"twenty":-17.753166,"median":-13.39003,"eighty":-9.064424,"marketCap":202847989},{"date":"2026-07-02","current":-7.524736,"twenty":-17.753166,"median":-10.756935,"eighty":-7.674051,"marketCap":221964554},{"date":"2026-07-10","current":-6.687968,"twenty":-17.753166,"median":-10.600843,"eighty":-7.470839,"marketCap":197537832},{"date":"2026-07-17","current":-5.950494,"twenty":-17.703333,"median":-10.394273,"eighty":-7.2635,"marketCap":177359237},{"date":"2026-07-24","current":-5.990968,"twenty":-17.616125,"median":-10.19196,"eighty":-7.15871,"marketCap":177890252},{"date":"2026-07-31","current":-5.701372,"twenty":-17.597437,"median":-10.084942,"eighty":-7.057391,"marketCap":170260212},{"date":"2026-08-07","current":-6.137986,"twenty":-17.522687,"median":-9.917992,"eighty":-6.810664,"marketCap":183029728},{"date":"2026-08-14","current":-6.239509,"twenty":-17.454165,"median":-9.793252,"eighty":-6.730479,"marketCap":187286234},{"date":"2026-08-21","current":-4.207016,"twenty":-17.441707,"median":-9.728074,"eighty":-6.591693,"marketCap":189239834},{"date":"2026-08-28","current":-5.61745,"twenty":-17.34827,"median":-9.659831,"eighty":-6.31363,"marketCap":251065348},{"date":"2026-09-04","current":-5.551208,"twenty":-17.285978,"median":-9.555453,"eighty":-6.177212,"marketCap":249452508},{"date":"2026-09-11","current":-5.179874,"twenty":-17.261061,"median":-9.448244,"eighty":-6.142393,"marketCap":232248887},{"date":"2026-09-18","current":-5.512013,"twenty":-17.186311,"median":-9.401978,"eighty":-6.005849,"marketCap":244076376},{"date":"2026-09-25","current":-4.959579,"twenty":-17.080415,"median":-9.355306,"eighty":-5.930873,"marketCap":217195718},{"date":"2026-09-30","current":-4.730282,"twenty":-17.005665,"median":-9.17019,"eighty":-5.866178,"marketCap":206443455}],"updateTime":1790923091352},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NGEN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2670424499","title":"NervGen Announces It Will Restate Its Audited Annual Financial Statements For The Year Ended December 31, 2025, And Its Unaudited Interim Financial Statements For The Quarter Ended June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2670424499","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670424499?lang=en_us&edition=fundamental","pubTime":"2026-09-26 04:34","pubTimestamp":1790368484,"startTime":"0","endTime":"0","summary":"Adjustments have no impact on cash and cash equivalents, cash runway, or business operations.Restatement is expected to reduce previously reported stock-based compensation expense, warrant liabilities, and accumulated","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/09/62007963/nervgen-announces-it-will-restate-its-audited-annual-financial-statements-year-ended-december-31-202","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","NGEN","LU1892829315.USD","BK4007","LU0266013472.USD","LU0077335932.USD","BK4192","LU1291159041.SGD","SCI","LU1989771016.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670424197","title":"NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments","url":"https://stock-news.laohu8.com/highlight/detail?id=2670424197","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670424197?lang=en_us&edition=fundamental","pubTime":"2026-09-26 04:31","pubTimestamp":1790368278,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nFWN45H0LC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670424173","title":"NervGen - Restatement Expected to Reduce Stock-Based Compensation Expense, Warrant Liabilities, and Accumulated Deficit","url":"https://stock-news.laohu8.com/highlight/detail?id=2670424173","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670424173?lang=en_us&edition=fundamental","pubTime":"2026-09-26 04:31","pubTimestamp":1790368278,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nFWN45H0LC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670424172","title":"NervGen - Adjustments Have no Impact on Cash, Cash Runway, or Business Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2670424172","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670424172?lang=en_us&edition=fundamental","pubTime":"2026-09-26 04:31","pubTimestamp":1790368278,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nFWN45H0LC:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670242412","title":"NervGen - to Restate Fy2025 Audited and Q2 2026 Unaudited Financial Statements","url":"https://stock-news.laohu8.com/highlight/detail?id=2670242412","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670242412?lang=en_us&edition=fundamental","pubTime":"2026-09-26 04:31","pubTimestamp":1790368278,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nFWN45H0LC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670426467","title":"Nervgen’s RESTORE Trial Moves Toward Launch: What NVG-291 Could Mean for NGEN Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2670426467","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670426467?lang=en_us&edition=fundamental","pubTime":"2026-09-26 00:31","pubTimestamp":1790353863,"startTime":"0","endTime":"0","summary":"Nervgen Pharma Corp ($NGEN) announced an update on their ongoing clinical study. The study, officially titled “A Trial Investigating the Efficacy a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nervgens-restore-trial-moves-toward-launch-what-nvg-291-could-mean-for-ngen-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nervgens-restore-trial-moves-toward-launch-what-nvg-291-could-mean-for-ngen-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","NVG","BK4211","NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669988284","title":"NervGen Pharma Switches Auditor to KPMG US from KPMG Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2669988284","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669988284?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:28","pubTimestamp":1790252902,"startTime":"0","endTime":"0","summary":"NervGen Pharma switches auditor to KPMG US from KPMG CanadaNervGen Pharma will replace KPMG Canada with KPMG US as its auditor effective Sept. 15, 2026.KPMG Canada resigned at the company’s request.No","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nNDL5Pl4md:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666580510","title":"NervGen to Host Inaugural R&D Day Webcast on NVG-291 Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2666580510","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666580510?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:32","pubTimestamp":1788953539,"startTime":"0","endTime":"0","summary":"NervGen to host inaugural R&D Day webcast on NVG-291 programNervGen scheduled an inaugural R&D Day webcast for Sept. 30, 2026, starting at 10 a.m. ET.The session will outline the NVG-291 program, incl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL78ZZjN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014039.USD","LU2210149790.SGD","IE00BQXX3D17.EUR","IE00BN0W2V16.EUR","IE00BQXX3F31.USD","BK4112","IE00B3QW5Z07.USD","BCDF","BK4007","IE00B64PRP62.GBP","SG9999014021.USD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","NDAQ","IE00BN0W2T93.GBP","BK4588","BK4585","LU0314104364.USD","SG9999014013.SGD","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014005.SGD","NGEN","IE00BQXX3C00.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659015237","title":"Nervgen Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659015237","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659015237?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:35","pubTimestamp":1786624528,"startTime":"0","endTime":"0","summary":"BRIEF-Nervgen Reports Second Quarter 2026 Financial Results And Provides Business UpdatesAug 13 (Reuters)-NervGen Pharma CorpNGEN.O:NERVGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATESSource text:ID:nGNX9SXjX0Further company coverage:NGEN.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUA1DRDGS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659154354","title":"NervGen Q2 2026 Loss Reflects Continued Spending on NVG-291, NVG-300 Development, Company Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2659154354","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659154354?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:08","pubTimestamp":1786622912,"startTime":"0","endTime":"0","summary":"NervGen Q2 2026 loss reflects continued spending on NVG-291, NVG-300 development, company saysNervGen’s commentary for the three and six months ended June 30, 2026 centered on continued spending tied ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL46qz6K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659159089","title":"Press Release: NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659159089","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659159089?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:30","pubTimestamp":1786620600,"startTime":"0","endTime":"0","summary":"-- Site activation and screening for the Phase 3 RESTORE study is expected. to begin in September 2026, with the first participant anticipated to be. -- Strengthened leadership team, appointing Keith Vendola, MD, MBA as Chief. Financial Officer and Marissa Volpe as SVP, Clinical Development.-- C$86.8 million  in cash and cash equivalents as of June. 30, 2026, which is expected to fund operations through anticipated. topline data readout from RESTORE in 1H 2028.-- Company plans to host inaugural R&D Day in Fall 2026, bringing together. activation and screening for the Phase 3 RESTORE study is expected to. a Phase 3 registrational study of NVG-291 in individuals with chronic. improvement in gait quality across established hallmarks of SCI-specific. strengthening the Company's balance sheet and extending its expected","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4192","LU1291159041.SGD","SCI","LU0077335932.USD","LU0266013472.USD","BK4007","LU1989771016.USD","LU1892829315.USD","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651171427","title":"NervGen Pharma price target lowered to $15 from $18 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2651171427","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651171427?lang=en_us&edition=fundamental","pubTime":"2026-07-14 18:00","pubTimestamp":1784023213,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on NervGen Pharma (NGEN) to $15 from $18 and keeps a Buy rating on the s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nervgen-pharma-price-target-lowered-to-15-from-18-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nervgen-pharma-price-target-lowered-to-15-from-18-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651214618","title":"Nervgen Pharma Initiated at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2651214618","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651214618?lang=en_us&edition=fundamental","pubTime":"2026-07-14 02:09","pubTimestamp":1783966140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NGEN/analyst-ratings(END) Dow Jones NewswiresJuly 13, 2026 14:09 ET","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651130118","title":"Nervgen Pharma Corp : Leerink Partners Initiates Coverage with Outperform Rating; Price Target $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2651130118","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651130118?lang=en_us&edition=fundamental","pubTime":"2026-07-13 18:07","pubTimestamp":1783937220,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43F0JM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648767635","title":"Nervgen Pharma Launches US$ 50 Million At-the-market Equity Offering Via Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2648767635","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648767635?lang=en_us&edition=fundamental","pubTime":"2026-07-03 05:24","pubTimestamp":1783027481,"startTime":"0","endTime":"0","summary":"NervGen Pharma launches US$ 50 million at-the-market equity offering via Leerink PartnersNervGen Pharma entered an at-the-market sales agreement with Leerink Partners to offer up to USD 50 million of ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL3xCpYv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MNSH","NGEN","BK4207"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646808486","title":"H.C. Wainwright Reaffirms Their Buy Rating on NervGen Pharma (NGEN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2646808486","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646808486?lang=en_us&edition=fundamental","pubTime":"2026-06-25 20:35","pubTimestamp":1782390956,"startTime":"0","endTime":"0","summary":"In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on NervGen Pharma, with a price target of $18.00. Selvaraju ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-nervgen-pharma-ngen-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-nervgen-pharma-ngen-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642280536","title":"H.C. Wainwright Reaffirms Their Buy Rating on NervGen Pharma (NGEN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642280536","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642280536?lang=en_us&edition=fundamental","pubTime":"2026-06-11 21:46","pubTimestamp":1781185574,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Ram Selvaraju maintained a Buy rating on NervGen Pharma on June 8 and set a price target of $18.00. Selvaraju covers the He...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-nervgen-pharma-ngen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-nervgen-pharma-ngen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642283168","title":"NervGen Pharma initiated with a Buy at TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2642283168","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642283168?lang=en_us&edition=fundamental","pubTime":"2026-06-11 17:51","pubTimestamp":1781171468,"startTime":"0","endTime":"0","summary":"TD Cowen initiated coverage of NervGen Pharma (NGEN) with a Buy rating and no price target The company is advancing treatments of neurotraumatic an...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nervgen-pharma-initiated-with-a-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nervgen-pharma-initiated-with-a-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGEN","BK4007","BK4566","BK4127","TD","BK4207","BK4585","COWN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640967937","title":"NervGen prices 24,000,000-share offering with warrants at US$2.5, targets US$60 million gross proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2640967937","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640967937?lang=en_us&edition=fundamental","pubTime":"2026-06-02 05:30","pubTimestamp":1780349414,"startTime":"0","endTime":"0","summary":"NervGen priced an underwritten follow-on public offering of 24,000,000 common shares with warrants to buy up to 24,000,000 shares.Offering price set at US$ 2.5 per common share and accompanying warrant; gross proceeds about US$ 60 million, excluding warrant exercises.Warrants carry a US$ 3.68 exercise price, are immediately exercisable, and expire five years from issuance.Net proceeds earmarked to advance NVG-291 clinical studies, with remaining funds for general corporate purposes.PFP Biosciences participated; post-offering stake 15,488,673 shares  with 8,144,335 warrants, capped at 19.99% ownership on exercise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NervGen Pharma Corp. published the original content used to generate this new","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL5jwN4t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639679718","title":"Nervgen’s CONNECT Trial Termination: What It Means for NGEN Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2639679718","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639679718?lang=en_us&edition=fundamental","pubTime":"2026-05-30 00:32","pubTimestamp":1780072349,"startTime":"0","endTime":"0","summary":"Nervgen Pharma Corp ($NGEN) announced an update on their ongoing clinical study. The CONNECT study, officially titled “A Randomized, Double-Blind, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nervgens-connect-trial-termination-what-it-means-for-ngen-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nervgens-connect-trial-termination-what-it-means-for-ngen-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","BK4211","NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":58,"code":"91000000","status":"200"}]}}